Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.
about
Immune response and immunopathology during toxoplasmosisCD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseasesThe CD8 T-cell road to immunotherapy of toxoplasmosis.Regulation of CD8+ T cell responses to infection with parasitic protozoa.Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondiiDifferential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival.Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii.Virulence of Toxoplasma gondii is associated with distinct dendritic cell responses and reduced numbers of activated CD8+ T cellsIL-21 is required for optimal antibody production and T cell responses during chronic Toxoplasma gondii infection.Enhancing in silico protein-based vaccine discovery for eukaryotic pathogens using predicted peptide-MHC binding and peptide conservation scores.CD8 T Cells and Toxoplasma gondii: A New ParadigmParasite fate and involvement of infected cells in the induction of CD4+ and CD8+ T cell responses to Toxoplasma gondii.Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination.Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infectionAntigen-specific T cells and cytokines detection as useful tool for understanding immunity against zoonotic infections.Nucleic acid transfection and transgenesis in parasitic nematodesAttenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.Role of CD4+ Foxp3+ Regulatory T Cells in Protection Induced by a Live Attenuated, Replicating Type I Vaccine Strain of Toxoplasma gondii.Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancerAvirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.Secretion of Rhoptry and Dense Granule Effector Proteins by Nonreplicating Toxoplasma gondii Uracil Auxotrophs Controls the Development of Antitumor Immunity.Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain.Cancer therapy in a microbial bottle: Uncorking the novel biology of the protozoan Toxoplasma gondii.Diverse roles for T-bet in the effector responses required for resistance to infection.DNA vaccination with genes encoding Toxoplasma gondii antigens ROP5 and GRA15 induces protective immunity against toxoplasmosis in Kunming mice.PD-L1, TIM-3, and CTLA-4 blockade fail to promote resistance to secondary infection with virulent strains of
P2860
Q24612341-E8F3FF63-A575-4B14-B1E9-B97718806BD4Q33732210-4D18ED9F-DD32-4E01-A4F3-E4B2DDD1588DQ33732215-5D91CBD9-2DB9-4DC7-84D8-5A25A0ACA74BQ34108177-AFED49E6-20B3-42A8-B4A3-B188E5F6F52AQ34119416-12522479-A36C-41EF-B76F-1ECE600E7235Q34151699-59286546-A903-40CA-B3E8-D0A8F4184DD4Q34365047-D8FEAF45-3735-44E9-A9F1-DD53E2942A95Q34577774-AC7B23A2-C8D6-4984-B34B-8C044D17E3E0Q34717852-51C3425C-AF42-44A3-8B42-E5A957575FABQ34783245-F2EFD864-B371-4DF8-BD1F-2B24811DAD5DQ35038836-DC41CA58-19B9-4005-8F5F-99F51DE930CAQ35145091-28390041-2501-4E71-B963-8B6622D629BFQ35172341-D2C95915-8FD5-47BC-B2EB-3582414F83A5Q35439431-68FAB9C2-C5D9-4B22-92FE-9CF064A0926DQ35779625-04A2DB57-90E2-4CB2-9894-89855EAAE396Q35869315-CD83F325-A088-4F4B-AD70-056F024660C3Q35920573-4196A18F-56E0-4F19-96FA-ED144E9C96DFQ35947458-574F09AD-0FC7-4186-81BC-E24C04147B48Q36821108-E9FA41C2-3ABB-4CA9-9434-08F17FDC2E97Q36986107-227A4616-7A06-4852-9DAE-972D956572C1Q37119146-CC41BC33-CC89-4E70-80F0-123A93931549Q37184436-48EF47F9-C391-4346-8744-FDB1F011873CQ37451015-C5A3DC5A-0615-4B55-A5B0-FC8AA8F7D656Q41068755-7740A9D0-CAB9-4918-AAE1-637F6644E685Q41565237-2F635B60-04BD-421B-98AE-DD0F5E2EABF3Q48292361-917B2412-A311-442E-92ED-CF00C77E044FQ56891292-2BE47C41-9BFD-4A27-9032-872A1EDFC837
P2860
Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.
@en
type
label
Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.
@en
prefLabel
Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.
@en
P2093
P2860
P356
P1476
Kinetics and phenotype of vaccine-induced CD8+ T-cell responses to Toxoplasma gondii.
@en
P2093
Barbara A Fox
Christopher A Hunter
David J Bzik
Emma H Wilson
Florence Dzierszinski
Kimberly A Jordan
P2860
P304
P356
10.1128/IAI.00024-09
P407
P577
2009-06-15T00:00:00Z